Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer

Oncogenic activation of protein kinase BRAF drives tumor growth by promoting mitogen-activated protein kinase (MAPK) pathway signaling. Because oncogenic mutations in BRAF occur in ∼2–7% of lung adenocarcinoma (LA), BRAF-mutant LA is the most frequent cause of BRAF-mutant cancer mortality worldwide....

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Proc Natl Acad Sci U S A
Autors principals: Okimoto, Ross A., Lin, Luping, Olivas, Victor, Chan, Elton, Markegard, Evan, Rymar, Andrey, Neel, Dana, Chen, Xiao, Hemmati, Golzar, Bollag, Gideon, Bivona, Trever G.
Format: Artigo
Idioma:Inglês
Publicat: National Academy of Sciences 2016
Matèries:
Biological Sciences
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5127364/
https://ncbi.nlm.nih.gov/pubmed/27834212
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1610456113
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars